Growing Service Offerings Acupath continually expands its test menu, introducing innovative panels like the BioFire GI Panel and bladder cancer biomarker, which indicates a strong focus on enhancing diagnostic capabilities and may present opportunities to cross-sell advanced testing solutions to current clients.

Strategic Partnerships Recent collaborations with Lumea for digital pathology solutions and Test Today for mobile COVID-19 testing demonstrate Acupath’s openness to leveraging technology and expanding service reach, suggesting potential for partnerships in telemedicine, remote diagnostics, and digital health initiatives.

Market Niche Expertise With specialized services in areas like Urology, Oncology, and Gastroenterology, Acupath serves highly targeted healthcare providers, making it ideal for sales outreach focused on sub-specialized labs and clinics looking to enhance diagnostic precision with cutting-edge tests.

Innovation Focus The launch of new clinically impactful products such as the FISH tests and the publication of white papers on biomarker utility indicate a commitment to innovation and thought leadership, presenting opportunities to engage industry leaders and hospitals seeking advancements in molecular diagnostics.

Growth and Reach Processing over 150,000 specimens annually for more than 500 active clients across the U.S., Acupath’s substantial volume and scalability highlight its potential as a partner for expanding diagnostic services and entering new regional or specialty markets through tailored solutions.